Compare BAFN & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | QSI |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 165.6M |
| IPO Year | 2021 | 2020 |
| Metric | BAFN | QSI |
|---|---|---|
| Price | $6.99 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.30 |
| AVG Volume (30 Days) | 103.5K | ★ 9.2M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.17 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,436,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $406.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.26 | $0.69 |
| 52 Week High | $9.80 | $2.44 |
| Indicator | BAFN | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 51.91 |
| Support Level | $5.98 | $1.14 |
| Resistance Level | $6.96 | $1.32 |
| Average True Range (ATR) | 0.62 | 0.17 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 58.04 | 22.31 |
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.